Immix Biopharma, Inc. (IMMX)

Immix Biopharma Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	-21.61	-15.43	-8.23	-24.38	-1.15
Depreciation & Amortization	0.12	0.01	0	0	0
Other Amortization	-	-	-	0.06	-
Stock-Based Compensation	3.02	2.57	0.62	0.22	-
Other Operating Activities	-0.08	-0.17	-	22.91	0.58
Change in Accounts Payable	4.4	2.43	1.13	-0.11	-0
Change in Income Taxes	-0.97	-0.89	-0.24	0.1	0.06
Change in Other Net Operating Assets	0.54	0.11	-0.7	-0.38	0.11
Operating Cash Flow	-14.6	-11.37	-7.41	-1.59	-0.4
Capital Expenditures	-1.18	-0.05	-	-0	-
Investing Cash Flow	-1.18	-0.05	-	-0	-
Long-Term Debt Issued	-	-	-	0.2	-
Total Debt Issued	-	-	-	0.2	-
Short-Term Debt Repaid	-	-	-0.05	-	-
Total Debt Repaid	-	-	-0.05	-	-
Net Debt Issued (Repaid)	-	-	-0.05	0.2	-
Issuance of Common Stock	15.95	15.52	2.91	18.65	-
Repurchase of Common Stock	-	-	-0.1	-	-
Other Financing Activities	-	-0.06	0.47	-	-
Financing Cash Flow	15.95	15.46	3.23	18.85	-
Foreign Exchange Rate Adjustments	-0	0.03	-0.03	-0.01	0.06
Miscellaneous Cash Flow Adjustments	0	-	-	-	-
Net Cash Flow	0.17	4.07	-4.21	17.25	-0.34
Free Cash Flow	-15.77	-11.42	-7.41	-1.59	-0.4
Free Cash Flow Per Share	-0.56	-0.66	-0.53	-0.43	-0.12
Cash Interest Paid	-	-	0.01	0	0
Cash Income Tax Paid	-	-	-	-	0.02
Levered Free Cash Flow	-7.55	-5.94	-4.31	-2.1	0.39
Unlevered Free Cash Flow	-7.55	-5.94	-4.31	-2.04	0.46
Change in Net Working Capital	-4.66	-1.63	-0.2	1.42	-0.74

Updated Nov 12, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q